{"id":9356,"date":"2025-12-09T14:32:59","date_gmt":"2025-12-09T11:32:59","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=9356"},"modified":"2025-12-09T14:33:00","modified_gmt":"2025-12-09T11:33:00","slug":"why-heart-failure-protocols-matter-global-evidence-that-gdmt-underuse-is-a-worldwide-problem-2025","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/why-heart-failure-protocols-matter-global-evidence-that-gdmt-underuse-is-a-worldwide-problem-2025\/","title":{"rendered":"Why Heart Failure Protocols Matter: Global Evidence That GDMT Underuse Is a Worldwide Problem (2025)"},"content":{"rendered":"<div>Why Heart Failure Protocols Matter: Global Evidence That GDMT Underuse Is a Worldwide Problem (2025)<\/div>\n<div><\/div>\n<div>Three major 2025 studies show clearly that underuse of GDMT is a global problem, spanning low-resource settings, primary care systems, and advanced European centers.<\/div>\n<div>National protocols are the proven first step to closing this implementation gap.<\/div>\n<div><\/div>\n<div>Keynotes:<\/div>\n<div>1) Implementation of Guideline-Directed Medical Therapy in HFrEF<\/div>\n<div><\/div>\n<div>Journal: BMC Cardiovascular Disorders<\/div>\n<div>Date: October 2025<\/div>\n<div>Setting: Hospital-based cohort in Ethiopia<\/div>\n<div>Link: https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-025-05187-5<\/div>\n<div><\/div>\n<div>Summary:<\/div>\n<div><span> \u2022 Only 1.3% of patients reached full target GDMT doses (RASI, \u03b2-blocker, MRA).<\/span><\/div>\n<div><span> \u2022 0% received ARNI or SGLT2i due to cost and limited availability.<\/span><\/div>\n<div><span> \u2022 Dose escalation was extremely rare even after treatment initiation.<\/span><\/div>\n<div><span> \u2022 Barriers were system-level: lack of structured protocols, weak follow-up, and resource limitations.<\/span><\/div>\n<div><span> \u2022 Conclusion: Improving GDMT requires national protocols, not individual physician effort.<\/span><\/div>\n<div><\/div>\n<div>2) Barriers and Facilitators to GDMT Intensification<\/div>\n<div><\/div>\n<div>Publisher: Springer \u2013 Journal of General Internal Medicine<\/div>\n<div>Date: 2025<\/div>\n<div>Setting: Multi-site U.S. primary care and community health centers<\/div>\n<div>Link: https:\/\/link.springer.com\/article\/10.1007\/s11606-025-09515-5<\/div>\n<div><\/div>\n<div>Key Findings:<\/div>\n<div><span> 1. Therapeutic inertia was the main barrier\u2014hesitation to escalate therapy even when indicated.<\/span><\/div>\n<div><span> 2. Time pressure and complex comorbidities made titration difficult.<\/span><\/div>\n<div><span> 3. Limited access to cardiologists created uncertainty in decision-making.<\/span><\/div>\n<div><span> 4. Conclusion: Clear national pathways reduce inertia, improve consistency, and accelerate GDMT adoption.<\/span><\/div>\n<div><\/div>\n<div>3) Implementation of Recommended HF Therapy in Europe<\/div>\n<div><\/div>\n<div>Journal: ESC Heart Failure<\/div>\n<div>Date: April 2025<\/div>\n<div>Link: https:\/\/pubmed.ncbi.nlm.nih.gov\/39632549\/<\/div>\n<div><\/div>\n<div>Key Findings:<\/div>\n<div><span> 1. Fewer than 50% of patients received all recommended GDMT drug classes.<\/span><\/div>\n<div><span> 2. Achieving target doses was even less common, demonstrating global under-titration.<\/span><\/div>\n<div><span> 3. Centers using structured pathways and registries had significantly better implementation.<\/span><\/div>\n<div><span> 4. The study confirms that guideline awareness \u2260 real-world practice.<\/span><\/div>\n<div><span> 5. Conclusion: Even Europe struggles\u2014proving the challenge is global, not local.<\/span><\/div>\n<div><\/div>\n<div>Why This Matters<\/div>\n<div><\/div>\n<div>Without Protocols:<\/div>\n<div><span> \u2022 Care varies by physician \u2192 inconsistent practice<\/span><\/div>\n<div><span> \u2022 No unified monitoring or follow-up<\/span><\/div>\n<div><span> \u2022 Dose escalation becomes rare \u2192 patients remain under-treated<\/span><\/div>\n<div><\/div>\n<div>With National Protocols:<\/div>\n<div><span> \u2022 Clear titration steps reduce therapeutic inertia<\/span><\/div>\n<div><span> \u2022 Unified referral pathways improve coordination across ED, cardiology, and primary care<\/span><\/div>\n<div><span> \u2022 Hospitals follow one standardized HF pathway, improving quality and reducing variation<\/span><\/div>\n<div><\/div>\n<div>This is why the world\u2019s leading systems \u2014 Europe, Canada, the U.S., Japan \u2014 all rely on national HF pathways.<\/div>\n<div><\/div>\n<div>Final Message to Physicians<\/div>\n<div><\/div>\n<div>Global data are clear: even top healthcare systems struggle with GDMT, and improvement only occurs after adopting unified national HF pathways.<\/div>\n<div>Launching national protocols is not cosmetic \u2014 it is the proven foundation for better outcomes.<\/div>\n<div>Jordan is now taking the same successful step that advanced systems took before achieving measurable progress.<\/div>\n<div>References (Direct Links)<\/div>\n<div><span> 1. BMC Cardiovascular Disorders (2025) \u2013 Implementation of GDMT<\/span><\/div>\n<div>https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-025-05187-5<\/div>\n<div><span> 2. Springer (2025) \u2013 Barriers and Facilitators to GDMT Intensification<\/span><\/div>\n<div>https:\/\/link.springer.com\/article\/10.1007\/s11606-025-09515-5<\/div>\n<div><span> 3. ESC Heart Failure (2025) \u2013 GDMT Implementation in Europe<\/span><\/div>\n<div><\/div>\n<div><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/39632549\/\">https:\/\/pubmed.ncbi.nlm.nih.gov\/39632549\/<\/a><\/div>\n<div><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Why Heart Failure Protocols Matter: Global Evidence That GDMT Underuse Is a Worldwide Problem (2025) Three major 2025 studies show clearly that underuse of GDMT is a global problem, spanning low-resource settings, primary care systems, and advanced European centers. National protocols are the proven first step to closing this implementation gap. Keynotes: 1) Implementation of [&hellip;]<\/p>\n","protected":false},"author":145,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-9356","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/9356","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/145"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=9356"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/9356\/revisions"}],"predecessor-version":[{"id":9357,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/9356\/revisions\/9357"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=9356"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=9356"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=9356"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}